The Solvay acquisition is the latest move by Dishman to acquire Western production assets. In 2006, it acquired the CMO Carbogen Amcis (Bubendorf, Switzerland), which included capabilities for high-potency APIs. In February 2006, it acquired I03S, Ltd. a
company specializing in ozone chemistry, and in 2005 acquired the UK-based contract research company Synprotec, Ltd.
Wuxi PharmaTech.
In China, the contract research and manufacturing firm Wuxi PharmaTech (Shanghai) is raising its position in the global market. The company is planning an US initial public offering (IPO) priced
to raise roughly $120 million. Wuxi PharmaTech's operations are grouped into two segments: laboratory services (consisting
of discovery chemistry, service biology, analytical, pharmaceutical development, and process development services) and manufacturing
(manufacturing of advanced intermediates and APIs) to 70 pharmaceutical and biotechnology customers, including nine of the
top 10 pharmaceutical companies, according to the company's prospectus.
Other companies move ahead
In another IPO, the drug-delivery and formulation company Eurand (Amsterdam) raised net proceeds of $100-million in the first half of 2007.
|
